<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083547</url>
  </required_header>
  <id_info>
    <org_study_id>CTC study</org_study_id>
    <nct_id>NCT04083547</nct_id>
  </id_info>
  <brief_title>Circulating Tumour Cells in Patients With Peritoneal Metastases</brief_title>
  <official_title>Cirkulerande Tumörceller Hos Patienter Med Bukhinnespridda tumörer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the prognostic value of circulating tumour cells (CTC) in&#xD;
      patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due&#xD;
      to gastrointestinal cancers that have spread to the peritoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTCs har extracted by way of a new method at baseline, during surgery, and postoperatively.&#xD;
      The occurence of such CTCs will be investigated for prognostic evaluation. Patients will be&#xD;
      follow-up by Clinical routine. Disease recurrence and overall survival will be the endpoint&#xD;
      used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value</measure>
    <time_frame>2 year.</time_frame>
    <description>Prediction of survival and recurrence according to the occurrence of CTCs.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">114</enrollment>
  <condition>Circulating Tumor Cell</condition>
  <condition>Peritoneal Metastases</condition>
  <condition>Hyperthermic Intraperitoneal Chemotherapy</condition>
  <arm_group>
    <arm_group_label>HIPEC group</arm_group_label>
    <description>All patients undergoing HIPEC will asked to join this prospective study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>iCellate</intervention_name>
    <description>New method of circulating tumour cell detection and capture.</description>
    <arm_group_label>HIPEC group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients being treated in Uppsala with CRS and HIPEC will be asked to join the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Peritoneal metastases being treated with cytoreductive surgery and hyperthermic&#xD;
             intraperitoneal chemotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Akademiska Sjukhuset (Uppsala University hospital)</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

